Michael Iskra, executive vice president of commercial excellence and strategy at Ortho, said his company is focused on delivering quality results and the operational financial impacts of diagnostic ...
Assay is now commercially available in the U.S. and countries accepting CE Mark RARITAN, New Jersey, March 8, 2018 /PRNewswire/ -- Ortho Clinical Diagnostics, a global leader of in vitro diagnostics, ...
Raritan’s Ortho Clinical Diagnostics Holdings plc and Quidel Corp., based in San Diego, on Dec. 23 announced entering a definitive agreement that will see Quidel acquire Ortho in a deal valued at ...
RARITAN, N.J., July 22, 2021 /CNW/ — Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world’s largest pure-play in vitro diagnostics companies, today announced its VITROS (R) Immunodiagnostic ...
RARITAN, N.J., Feb. 4, 2021 /PRNewswire/ -- Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX) ("Ortho"), the world's largest pure-play in vitro diagnostics company dedicated to improving and ...
Ortho Clinical Diagnostics (Ortho) and EKF Diagnostics (EKF) announced an agreement that allows Ortho customers to access EKF’s Stanbio Chemistry Beta-Hydroxybutyrate (BHB) LiquiColor® assay. This is ...
RARITAN, N.J., March 21, 2019 /PRNewswire/ -- Ortho Clinical Diagnostics, a global leader of in vitro diagnostics, announced the launch of four new key assays to meet the demand of the rapidly growing ...
RARITAN, N.J., April 26, 2021 /CNW/ — Ortho Clinical Diagnostics (NASDAQ: OCDX), one of the world’s largest pure-play in vitro diagnostics (IVD) companies, has been recognized with a prestigious ...
RARITAN, New Jersey and SINGAPORE, May 14, 2019 /PRNewswire/ -- Ortho Clinical Diagnostics, a global leader of in vitro diagnostics, in collaboration with Singapore Management University, will host ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback